| 000 | 01759 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250515002000.0 | ||
| 264 | 0 | _c20051209 | |
| 008 | 200512s 0 0 spa d | ||
| 022 | _a0325-7541 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aValerga, M | |
| 245 | 0 | 0 |
_a[Mycobacterium bovis tuberculosis in a female patient with AIDS]. _h[electronic resource] |
| 260 |
_bRevista Argentina de microbiologia _c |
||
| 300 |
_a96-8 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article | ||
| 650 | 0 | 4 |
_aAIDS-Related Opportunistic Infections _xmicrobiology |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAlcoholism _xcomplications |
| 650 | 0 | 4 |
_aAntitubercular Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aArgentina _xepidemiology |
| 650 | 0 | 4 |
_aCocaine-Related Disorders _xcomplications |
| 650 | 0 | 4 | _aDisease Susceptibility |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aEthambutol _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIsoniazid _xtherapeutic use |
| 650 | 0 | 4 |
_aMeningitis, Cryptococcal _xcomplications |
| 650 | 0 | 4 |
_aMycobacterium bovis _xdrug effects |
| 650 | 0 | 4 |
_aOfloxacin _xtherapeutic use |
| 650 | 0 | 4 |
_aPneumocystis carinii _xisolation & purification |
| 650 | 0 | 4 |
_aPneumonia, Pneumocystis _xcomplications |
| 650 | 0 | 4 |
_aPyrazinamide _xpharmacology |
| 650 | 0 | 4 |
_aRifampin _xpharmacology |
| 650 | 0 | 4 |
_aTuberculosis, Miliary _xcomplications |
| 650 | 0 | 4 |
_aTuberculosis, Multidrug-Resistant _xcomplications |
| 650 | 0 | 4 |
_aTuberculosis, Pulmonary _xcomplications |
| 700 | 1 | _aViola, C | |
| 700 | 1 | _aThwaites, A | |
| 700 | 1 | _aBases, O | |
| 700 | 1 | _aAmbroggi, M | |
| 700 | 1 | _aPoggi, S | |
| 700 | 1 | _aMarino, R | |
| 773 | 0 |
_tRevista Argentina de microbiologia _gvol. 37 _gno. 2 _gp. 96-8 |
|
| 999 |
_c15810348 _d15810348 |
||